Paper36968951
Impact of ompk36 genotype and KPC subtype on the in vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam against KPC-producing K. pneumoniae clinical isolates.
Rogers TM and 6 others. JAC Antimicrob Resist, 2023. Cited by 19 papers, by iCite.
Cite this record
ConductScience Library. Impact of ompk36 genotype and KPC subtype on the in vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam against KPC-producing K. pneumoniae clinical isolates. Papers, record 36968951. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36968951
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Impact of ompk36 genotype and KPC subtype on the in vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam against KPC-producing K. pneumoniae clinical isolates.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R03 AI144636 | NIAID NIH HHS | United States | R03AI144636 | PubMed | NIH RePORTER |
| R21 AI151363 | NIAID NIH HHS | United States | R21AI151363 | PubMed | NIH RePORTER |
References34
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26349830 | Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects. | Antimicrob Agents Chemother | 2015 | https://conductscience.org/library/papers/26349830 | PubMed |
| 2 | 34901302 | Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections. | Open Forum Infect Dis | 2021 | https://conductscience.org/library/papers/34901302 | PubMed |
| 3 | 35065702 | Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. | Lancet | 2022 | https://conductscience.org/library/papers/35065702 | PubMed |
| 4 | 29914955 | Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants. | Antimicrob Agents Chemother | 2018 | https://conductscience.org/library/papers/29914955 | PubMed |
| 5 | 29038260 | Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae. | Antimicrob Agents Chemother | 2017 | https://conductscience.org/library/papers/29038260 | PubMed |
| 6 | 35373297 | Dynamic evolution of imipenem/relebactam resistance in a KPC-producing Klebsiella pneumoniae from a single patient during ceftazidime/avibactam-based treatments. | J Antimicrob Chemother | 2022 | https://conductscience.org/library/papers/35373297 | PubMed |
| 7 | 23459476 | Characterization of porin expression in Klebsiella pneumoniae Carbapenemase (KPC)-producing K. pneumoniae identifies isolates most susceptible to the combination of colistin and carbapenems. | Antimicrob Agents Chemother | 2013 | https://conductscience.org/library/papers/23459476 | PubMed |
| 8 | 36154170 | In Vitro Mechanisms of Resistance Development to Imipenem-Relebactam in KPC-Producing Klebsiella pneumoniae. | Antimicrob Agents Chemother | 2022 | https://conductscience.org/library/papers/36154170 | PubMed |
| 9 | 33820773 | In Vitro Susceptibility of Multidrug-Resistant Pseudomonas aeruginosa following Treatment-Emergent Resistance to Ceftolozane-Tazobactam. | Antimicrob Agents Chemother | 2021 | https://conductscience.org/library/papers/33820773 | PubMed |
| 10 | 26169413 | Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum β-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae. | Antimicrob Agents Chemother | 2015 | https://conductscience.org/library/papers/26169413 | PubMed |
| 11 | 28630202 | Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae. | Antimicrob Agents Chemother | 2017 | https://conductscience.org/library/papers/28630202 | PubMed |
| 12 | 23939888 | Mutations of the ompK36 porin gene and promoter impact responses of sequence type 258, KPC-2-producing Klebsiella pneumoniae strains to doripenem and doripenem-colistin. | Antimicrob Agents Chemother | 2013 | https://conductscience.org/library/papers/23939888 | PubMed |
| 13 | 33106864 | Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). | Clin Infect Dis | 2021 | https://conductscience.org/library/papers/33106864 | PubMed |
| 14 | 28848018 | Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae. | Antimicrob Agents Chemother | 2017 | https://conductscience.org/library/papers/28848018 | PubMed |
| 15 | 36374023 | Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints. | Antimicrob Agents Chemother | 2022 | https://conductscience.org/library/papers/36374023 | PubMed |
| 16 | 34923128 | European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). | Clin Microbiol Infect | 2022 | https://conductscience.org/library/papers/34923128 | PubMed |
| 17 | 35416711 | Increased blaKPC Copy Number and OmpK35 and OmpK36 Porins Disruption Mediated Resistance to Imipenem/Relebactam and Meropenem/Vaborbactam in a KPC-Producing Klebsiella pneumoniae Clinical Isolate. | Antimicrob Agents Chemother | 2022 | https://conductscience.org/library/papers/35416711 | PubMed |
| 18 | 31477712 | OmpK36-mediated Carbapenem resistance attenuates ST258 Klebsiella pneumoniae in vivo. | Nat Commun | 2019 | https://conductscience.org/library/papers/31477712 | PubMed |
| 19 | 32151332 | Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study. | Lancet Infect Dis | 2020 | https://conductscience.org/library/papers/32151332 | PubMed |
| 20 | 30617090 | Effects of KPC Variant and Porin Genotype on the In Vitro Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae. | Antimicrob Agents Chemother | 2019 | https://conductscience.org/library/papers/30617090 | PubMed |
Cited by14
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 19 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42267316 | Carbapenemases: epidemiology, detection and management in a changing global landscape. | JAC Antimicrob Resist | 2026 | https://conductscience.org/library/papers/42267316 | PubMed |
| 42136902 | Successful Treatment with Imipenem/Cilastatin/ Relebactam of a Polymicrobial Bacteremia due to Meropenem/Vaborbactam-Resistant KPC-Kp and Enterococcus Faecalis. | Mediterr J Hematol Infect Dis | 2026 | https://conductscience.org/library/papers/42136902 | PubMed |
| 42106608 | Genomic and molecular characterisation of a KPC-producing Klebsiella pneumoniae clinical isolate resistant to meropenem-vaborbactam, imipenem-relebactam, and ceftazidime-avibactam. | BMC Genom Data | 2026 | https://conductscience.org/library/papers/42106608 | PubMed |
| 41892432 | Novel Insights into Carbapenem Resistance: Mechanisms, Diagnostics, and Future Directions. | Antibiotics (Basel) | 2026 | https://conductscience.org/library/papers/41892432 | PubMed |
| 41777542 | First identification of an ST11-KL64 hypervirulent Klebsiella pneumoniae strain coproducing KPC-2 and NDM-1 with an OmpK36 GD mutation. | Front Microbiol | 2026 | https://conductscience.org/library/papers/41777542 | PubMed |
| 41608681 | Molecular resistance mechanisms to newly approved antibiotics (2017-2025) in WHO priority pathogens. | Front Microbiol | 2025 | https://conductscience.org/library/papers/41608681 | PubMed |
| 41436714 | Emergence of resistance to novel β-lactam/β-lactamase inhibitor combinations in KPC-producing Klebsiella pneumoniae: clinical and genomic insights from consecutive bloodstream infections. | Infection | 2026 | https://conductscience.org/library/papers/41436714 | PubMed |
| 41258724 | Unlocking potentials: the impact of meropenem, meropenem-vaborbactam, and ceftazidime-avibactam in combating carbapenem-resistant Enterobacter cloacae. | Antimicrob Agents Chemother | 2025 | https://conductscience.org/library/papers/41258724 | PubMed |
| 40223126 | Activity of imipenem/relebactam against KPC-producing Klebsiella pneumoniae and the possible role of Ompk36 mutation in determining resistance: an Italian retrospective analysis. | Ann Clin Microbiol Antimicrob | 2025 | https://conductscience.org/library/papers/40223126 | PubMed |
| 39239090 | Emergence of high-level aztreonam-avibactam and cefiderocol resistance following treatment of an NDM-producing Escherichia coli bloodstream isolate exhibiting reduced susceptibility to both agents at baseline. | JAC Antimicrob Resist | 2024 | https://conductscience.org/library/papers/39239090 | PubMed |
| 38426743 | In vitro activity of meropenem-vaborbactam plus aztreonam against metallo-β-lactamase-producing Klebsiella pneumoniae. | Antimicrob Agents Chemother | 2024 | https://conductscience.org/library/papers/38426743 | PubMed |
| 37901589 | Mutations in ompK36 differentially impact in vitro synergy of meropenem/vaborbactam and ceftazidime/avibactam in combination with other antibiotics against KPC-producing Klebsiella pneumoniae. | JAC Antimicrob Resist | 2023 | https://conductscience.org/library/papers/37901589 | PubMed |
| 37887222 | Ceftazidime/Avibactam and Meropenem/Vaborbactam for the Management of Enterobacterales Infections: A Narrative Review, Clinical Considerations, and Expert Opinion. | Antibiotics (Basel) | 2023 | https://conductscience.org/library/papers/37887222 | PubMed |
| 37764198 | A Whole-Genome Sequencing-Based Approach for the Characterization of Klebsiella pneumoniae Co-Producing KPC and OXA-48-like Carbapenemases Circulating in Sardinia, Italy. | Microorganisms | 2023 | https://conductscience.org/library/papers/37764198 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| IS5 | 100190985 | PubTator's text mining | https://conductscience.org/library/genes/100190985 | NCBI Gene |
| UBAC1 | 10422 | PubTator's text mining | https://conductscience.org/library/genes/10422 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36968951
GET https://conductscience.org/api/papers/v1/36968951/references?page=2